Evidence map›Paper›PMID 39339192›Full record

ArticlePharmaceutics2024

Cationic Curcumin Nanocrystals Liposomes for Improved Oral Bioavailability: Formulation Development, Optimization, In Vitro and In Vivo Evaluation.

Xiang Cheng, Xiaoran Han, Jia Si, Cong Dong, Zhongjuan Ji, Shicong Zhao, Xiangting Wu, Haiyan Li, Xiangqun Jin

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiang ChengDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Xiaoran HanDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Jia SiDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Cong DongDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Zhongjuan JiDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Shicong ZhaoDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Xiangting WuDepartment of Pharmacy, Jilin University, Changchun 130021, China.
Haiyan LiDepartment of Pharmacy, Changchun University of Chinese Medicine, Changchun 130021, China.
Xiangqun JinDepartment of Pharmacy, Jilin University, Changchun 130021, China.

Funding

Jilin Province Science and Technology Department No. 20220401107YY
6 · The paper itself

Abstract

Curcumin, a naturally occurring poorly water-soluble polyphenol with a broad spectrum, is a typical BCS IV drug. The objective of this study was to develop curcumin nanocrystals liposomes with the aim of improving bioavailability. In this study, we prepared cationic curcumin nanocrystals with a particle size of only 29.42 nm; such a phenomenal range of particle sizes is very rare. Moreover, we summarized and evaluated the parameters of the nanocrystal preparation process, including methods, formulations, etc., and the rules we concluded can be generalized to other nanocrystal preparation processes. To counteract the instability of the nanocrystals in the digestive tract, cationic curcumin nanocrystals were loaded into negatively charged liposomes through gravitational force between different charges. Unexpectedly, chitosan oligosaccharide was found to promote the self-assembly process of curcumin nanocrystal liposomes. In vitro and in vivo experiments demonstrated that chitosan-modified curcumin nanocrystal liposomes exhibited enhanced resistance to enzyme barriers, mucus barriers, and cellular barriers, resulting in a 5.4-fold increase in bioavailability compared to crude powder formulations. It can be concluded that cationic nanocrystals liposomes represent an appropriate novel strategy for improving the dissolution rate and bioavailability of poorly soluble natural products such as curcumin.

Indexed as

bioavailability enhancementcationic nanocrystalscurcuminmucous barrieroral absorption

Identifiers

PMID39339192
PMCPMC11434666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.